Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

NCT ID: NCT06070012 Phase: PHASE2 Sponsor: Diwakar Davar Status: Recruiting

SUMMARY

This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.

KEY ELIGIBILITY CRITERIA

- Histologically or cytologically confirmed untreated metastatic uveal melanoma (mUM).
- HLA-A*0201 genotype positive as assessed using a CLIA-certified blood typing method and confirmed by central review.
- * If HLA-A status is not known, blood for HLA-A testing must be submitted during Screening, and HLA-A*0201 positive status confirmed prior to enrollment using a CLIA- certified blood typing method.
- * If the patient is known to be HLA-A*0201 positive, this information must be provided in the Screening packet and centrally reviewed by treating PI and Sponsor-Investigator prior to enrollment.
- * The following HLA testing methodologies are suitable to determine HLA-A*0201 positivity:
- * Multiplex real-time PCR based testing performed by entities including but not limited to Labcorp, and American Red Cross.
- * HLA testing as part of peripheral blood molecular profiling technology including but not limited to Caris Life Sciences Molecular Profiling Technology.
- * Patients be willing to undergo ctDNA assessment using Signatera assay.
- * Have provided newly obtained core biopsy of a tumor lesion not previously irradiated.
- * Adequate organ function on screening labs obtained within 4 weeks of Week 1 day 1

ENROLLMENT CONTACT

Kathy Prinz, CRC
University of Colorado Cancer Center
Aurora, Colorado, United States
Phone: 303-724-9815
Email: kathy.prinz@cuanschutz.edu

Total sites: 4 | 4 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT06070012) and public sources. Generated by FindMyCure.ai.